BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

679 related articles for article (PubMed ID: 9257781)

  • 1. Hymenoptera sting anaphylaxis and urticaria pigmentosa: clinical findings and results of venom immunotherapy in ten patients.
    Fricker M; Helbling A; Schwartz L; Müller U
    J Allergy Clin Immunol; 1997 Jul; 100(1):11-5. PubMed ID: 9257781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anaphylactoid shock following Hymenoptera sting as a presenting symptom of systemic mastocytosis.
    Kors JW; van Doormaal JJ; de Monchy JG
    J Intern Med; 1993 Mar; 233(3):255-8. PubMed ID: 8450293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hymenoptera venom allergy.
    Przybilla B; Ruëff F
    J Dtsch Dermatol Ges; 2010 Feb; 8(2):114-27; quiz 128-30. PubMed ID: 19751222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated basal serum tryptase and hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy.
    Haeberli G; Brönnimann M; Hunziker T; Müller U
    Clin Exp Allergy; 2003 Sep; 33(9):1216-20. PubMed ID: 12956741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of venom immunotherapy on serum level of CCL5/RANTES in patients with Hymenoptera venom allergy.
    Gawlik R; Glück J; Jawor B; Rogala B
    Immunopharmacol Immunotoxicol; 2015; 37(4):375-9. PubMed ID: 26181651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rush hymenoptera venom immunotherapy is efficacious and safe.
    Pasaoglu G; Sin BA; Misirligil Z
    J Investig Allergol Clin Immunol; 2006; 16(4):232-8. PubMed ID: 16889280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age-dependent sting recurrence and outcome in immunotherapy-treated children with anaphylaxis to Hymenoptera venom.
    Stritzke AI; Eng PA
    Clin Exp Allergy; 2013 Aug; 43(8):950-5. PubMed ID: 23889248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discontinuation of yellow jacket venom immunotherapy: follow-up of 75 patients by means of deliberate sting challenge.
    van Halteren HK; van der Linden PW; Burgers JA; Bartelink AK
    J Allergy Clin Immunol; 1997 Dec; 100(6 Pt 1):767-70. PubMed ID: 9438484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anaphylaxis after Hymenoptera sting without detectable specific IgE.
    Zidarn M; Kosnik M; Drinovec I
    Acta Dermatovenerol Alp Pannonica Adriat; 2007 Mar; 16(1):31-3. PubMed ID: 17992452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses.
    Ruëff F; Wenderoth A; Przybilla B
    J Allergy Clin Immunol; 2001 Dec; 108(6):1027-32. PubMed ID: 11742283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rush Hymenoptera venom immunotherapy: successful treatment in a patient with systemic mast cell disease.
    Engler RJ; Davis WS
    J Allergy Clin Immunol; 1994 Sep; 94(3 Pt 1):556-9. PubMed ID: 8083461
    [No Abstract]   [Full Text] [Related]  

  • 12. Honeybee and wasp venom allergy: Sensitization and immunotherapy.
    Adib-Tezer H; Bayerl C
    J Dtsch Dermatol Ges; 2018 Oct; 16(10):1228-1247. PubMed ID: 30300499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoblot studies in allergic patients to hymenoptera venom before and during immunotherapy.
    Pereira Santos MC; Pedro E; Spínola Santos A; Branco Ferreira M; Palma Carlos ML; Palma Carlos AG
    Eur Ann Allergy Clin Immunol; 2005 Sep; 37(7):273-8. PubMed ID: 16285233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunotherapy against hymenoptera venom: report of ten patients].
    Guzmán M MA; Salinas L J; Toche P P; Marinovic M MA; Gallardo O AM
    Rev Med Chil; 2007 Dec; 135(12):1566-71. PubMed ID: 18357358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Desensitization of allergy to hymenoptera venoms].
    Przybilla B; Ruëff F
    Wien Med Wochenschr; 1999; 149(14-15):421-8. PubMed ID: 10584286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anaphylaxis after Hymenoptera stings in three patients with urticaria pigmentosa.
    Müller UR; Horat W; Wüthrich B; Conroy M; Reisman RE
    J Allergy Clin Immunol; 1983 Dec; 72(6):685-9. PubMed ID: 6196389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic and local reactions of bee venom immunotherapy in Iran.
    Bemanian MH; Farhoudi A; Pourpak Z; Gharagozlou M; Movahedi M; Nabavi M; Mozafari H; Mohammadzadeh I; Chavoshzadeh Z; Shirkhoda Z
    Iran J Allergy Asthma Immunol; 2007 Dec; 6(4):203-6. PubMed ID: 18094443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety profile of hymenoptera venom immunotherapy (VIT) in monosensitized patients: lack of new sensitization to nontreated insect venom.
    Spoerl D; Bircher AJ; Scherer K
    J Investig Allergol Clin Immunol; 2011; 21(1):22-7. PubMed ID: 21370719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology, diagnosis, and treatment of Hymenoptera venom allergy in mastocytosis patients.
    Niedoszytko M; Bonadonna P; Oude Elberink JN; Golden DB
    Immunol Allergy Clin North Am; 2014 May; 34(2):365-81. PubMed ID: 24745680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk assessment of Hymenoptera re-sting frequency: implications for decision-making in venom immunotherapy.
    von Moos S; Graf N; Johansen P; Müllner G; Kündig TM; Senti G
    Int Arch Allergy Immunol; 2013; 160(1):86-92. PubMed ID: 22948338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.